Esposito G, Sucderi C, Valenza M, Togna GI, Latina V, De Filippis D, Cipriano M, Carratú MR, Iovone T, Sreardo L. Cannabidiol Reduces Aβ-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPARγ Involvement. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3230631/ (14 de agosto de 2017)
Inducible nitrous oxide synthase (iNOS) activity is increased in IPF and this increase correlates with the progress of the disease. Inhibitors of this enzyme have shown to have an antifibrotic effect in animal models (mice).
Pulmonary fibrosis with the loss of the fine lung vasculature eventually affects the heart as the result of an increase in pressure in the pulmonary arteries which the heart must overcome to pump blood to the lung for oxygenation.
Esposito G, De Filippis D, Maiuri MC, De Stefano D, Carnuccio R, Iuvone T. Cannabidiol inhibits inducible nitric oxide sythase protein expression and nitric oxide production in beta-amiloid situmalted PC12 neurons throug p38 MAP kinase and NF-kappaB involvement. http://www.sciencedirect.com/science/article/pii/S0304394006000681?via%3Dihub (14 de agosto de 2017)
Symptoms include progressive respiratory difficulty as the disease advances. Blood oxygenation levels gradually fall, initially in common activities and then even with the most minimal movements. This evolution is generally rapid, taking between some months and some years, but in some cases, it is much slower.
1. Cinar R, Gochuico BR, Iyer M, Yokoyama T, Park JK, Coffey NJ, Jourdan T, Gahl WA and Kunos G. Laboratorio de Estudios Fisiológicos de NIAAA y Medical Genetic Branch de NHGRI
Fernández-Ruiz J, Saagredo O, Pazos, MR, García C, Pertwee R, Mechoulam R, Marínez-Orgado J. Cannabidiol for neurodegenerative disorders:important new clinical applications for this phytocannabinoid? Br J Clin Pharmacology. 2013 Feb; 75(2):323-333 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579248/ (14 de agosto de 2017)
About Idiopathic Pulmonary Fibrosis
The FDA’s Office of Orphan Drug Products grants Orphan Drug Designation to support drug candidates in development for underserved patient populations or rare disorders that affect fewer than 200,000 people in the U.S. Orphan Drug Designation qualifies a candidate for various development incentives, including tax credits for eligible clinical trials, waiver of application fees, and market exclusivity for seven years upon FDA approval.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company’s pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor.